Therapy of small cell lung cancer with emphasis on oral topotecan

被引：12

作者：

Pirker, Robert ^{[1
]}

Berzinec, Peter ^{[2
]}

Brincat, Stephen ^{[3
]}

Kasan, Peter ^{[4
]}

Ostoros, Gyula ^{[5
]}

Pesek, Milos ^{[6
]}

Plate, Signe ^{[7
]}

Purkalne, Gunta ^{[8
]}

Rooneem, Regina ^{[9
]}

Skrickova, Jana ^{[10
]}

Stanculeanu, Dana ^{[11
]}

Timcheva, Constanta ^{[12
]}

Tzekova, Valentina ^{[13
]}

Zakotnik, Branko ^{[14
]}

Zielinski, Christoph C. ^{[1
]}

Zwitter, Matjaz ^{[15
]}

机构：

[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria

[2] Specialised Hosp St Zoerardus Zobor, Dept Oncol, Nitra, Slovakia

[3] Sir Paul Boffa Hosp, Floriana, Malta

[4] Univ Hosp Bratislava, Dept Oncol, Bratislava, Slovakia

[5] Natl Koranyi Inst TB & Pulmonol, Budapest, Hungary

[6] Charles Univ Prague, Fac Med, Plzen, Czech Republic

[7] Riga Easten Univ Hosp, Riga, Latvia

[8] Paul Stradins Clin Univ Hosp Riga, Radiat & Chemotherapy Ctr, Riga, Latvia

[9] N Estonia Reg Hosp, Ctr Canc, Dept Chemotherapy, Tallinn, Estonia

[10] Univ Hosp, Dept Resp Dis & TB, Brno, Czech Republic

[11] Inst Oncol, Bucharest, Romania

[12] Specialized Hosp Active Treatment Oncol, Sofia, Bulgaria

[13] ISUL, Univ Hosp Queen Joanna, Clin Chemotherapy, Sofia, Bulgaria

[14] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia

[15] Inst Oncol Ljubljana, Dept Radiat Oncol, Ljubljana, Slovenia

来源：

LUNG CANCER | 2010年 / 70卷 / 01期

关键词：

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan; PROPHYLACTIC CRANIAL IRRADIATION; PREVIOUSLY UNTREATED PATIENTS; CISPLATIN PLUS ETOPOSIDE; LONG-TERM SURVIVAL; PHASE-III TRIAL; PROGNOSTIC-FACTORS; THORACIC RADIOTHERAPY; 2ND-LINE TREATMENT; CHEMOTHERAPY; AMRUBICIN;

D O I：

10.1016/j.lungcan.2010.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 13

页数：7

共 50 条

[21] Topotecan for relapsed small cell lung cancer: retrospective study
Alegria, Ana M.
Rodrigues, Cidalia
Teixeira, Encarnacao
Barata, Fernando
Sotto-Mayor, Renato
Figueiredo, Ana
Rito, Emilia
Almeida, Antonio B.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S805 - S805
[22] Topotecan in the treatment of recurrent small-cell lung cancer
Denisso, Tadeusz
Krzakowski, Maciej
ONCOLOGY IN CLINICAL PRACTICE, 2006, 2 (03): : 99 - 104
[23] Topotecan in the treatment of non-small cell lung cancer
Perez-Soler, R
SEMINARS IN ONCOLOGY, 1997, 24 (06) : S34 - S41
[24] Topotecan in the treatment of recurrent small cell lung cancer: An update
Ardizzoni, A
ONCOLOGIST, 2004, 9 : 4 - 13
[25] Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer
Tae, Jung Hyun
Lee, Jin Hwa
Kim, Yoon Kyung
Sim, Yun Su
Lee, Kyung Jong
Noh, Young Wook
Park, Jae Jung
Ryu, Yon Ju
Chun, Eun Mi
Chang, Jung Hyun
TUBERCULOSIS AND RESPIRATORY DISEASES, 2008, 65 (02) : 142 - 146
[26] Topotecan - A review of its efficacy in small cell lung cancer
Ormrod, D
Spencer, CM
DRUGS, 1999, 58 (03) : 533 - 551
[27] Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status
Lilenbaum, Rogerio C.
Huber, Rudolf M.
Treat, Joseph
Masters, Gregory
Kaubitzsch, Sabine
Lane, Stephen
Wissel, Paul
CLINICAL LUNG CANCER, 2006, 8 (02) : 130 - 134
[28] Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer
Eckardt, JR
ONCOLOGY, 2001, 61 : 30 - 34
[29] Oral targeted therapy for non-small cell lung cancer
Phillips, William J.
Leighl, Natasha B.
Blais, Normand
Wheatley-Price, Paul
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (22) : E770 - E774
[30] ORAL-THERAPY FOR SMALL-CELL LUNG-CANCER
POSTMUS, PE
SMIT, EF
LUNG CANCER, 1995, 12 : S63 - S70

← 1 2 3 4 5 →